Abstract
The coronary collateral circulation can reduce sudden cardiac death,myocardial cell loss,and infarct size.Growth differentiation factor 15(GDF-15),a member of the transforming growth factor-beta (TGF-beta) superfamily,has been reported to have a prognostic predicting value in coronary artery disease. GDF-15 can be related with the extent of collateral formation. Growth differentiation factor 15 (GDF-15), a member of the transforming growth factor-beta (TGF-beta) superfamily, has been reported to have a prognostic predicting value in coronary artery disease. We sought to investigate whether GDF-15 is related to coronary collateral development in patients with coronary heart disease. A cross-sectional study was performed in 201 patients, who were admitted for selective coronary angiography. Patients were divided into 3 groups based on Rentrop's classification of coronary collaterals. Group 1: patients with coronary collateral presence, which was defined by Rentrop's grade 1-3 collateral development. Group 2: patients with grade 0 collateral development. Group 3: control group were patients with a normal coronary angiogram. The levels of plasma GDF-15, asymmetric dimethylarginine (ADMA), and soluble Fms-related tyrosine kinase-1 (sFLT-1) were compared among the 3 groups. There were significant statistical differences in plasma sFLT-1, ADMA, and GDF-15 concentrations among the different collateral groups. The correlations between Rentrop's grade and the cytokines were significant. A positive correlation was found between Rentrop's grade and GDF-15 (r = 0.187, P < 0.05). The correlations between the levels of plasma sFLT-1, ADMA, and Rentrop's grade were significant, with the correlation coefficient of r = 0.181, P < 0.05 (sFLT-1) and r = - 0.646, P < 0.001 (ADMA), respectively. Our findings suggest that GDF-15 levels increase with the extent of collateral formation. In that case, the patients with a higher level of GDF-15 may predict more severe coronary stenosis, which has a higher probability to develop collaterals.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
